Prescription of statins according to the ASCVD estimator at Pablo Arturo Suarez Hospital, March 2021 to February 2022

Prescription of statins according to the ASCVD estimator at Pablo Arturo Suarez Hospital, March 2021 to February 2022

Main Article Content

Jordan Llerena Velastegui
Sebastian Velastegui Zurita
Ana Teran Lopez


Globally, the leading cause of death is cardiovascular disease. The study details the prescription of statins at the Pablo Arturo Suarez Hospital in Ecuador between March 2021 and February 2022 following the ASCVD risk scale of the American College of Cardiology and the American Heart Association. There are 563 people in this cross-sectional and retrospective study: 70% women, 30% men, 93.30% mestizos, 48.10% diabetics, 62.30% hypertensives, and 18.70% smokers. 26.10% of all patients received statins, with simvastatin being the most common (96.60%). The mean cardiovascular risk in the general population was 15.52 ± 14.51%, 44.99% of subjects had a risk lower than 7.50%, and 29% had a risk higher than 20%, with a statistically significant difference (p<0.001) according to sex. The study determined that 58.60% of the population received a statin or an inadequate dosage of it.


Acevedo, M. et al. (2017) “Evaluation the American College of Cardiology and American Heart Association Predictive score for cardiovascular diseases,” Revista medica de Chile, 145(3), pp. 292–298. doi: 10.4067/S0034-98872017000300002.

Azevedo, T. dos A., Moreira, M. L. V. and Nucera, A. P. C. dos S. (2018) “Cardiovascular risk estimation by the ASCVD risk estimator application in a university hospital,” International Journal of Cardiovascular Sciences. doi: 10.5935/2359-4802.20180052.

Barceló, A. (2006) “Cardiovascular diseases in Latin America and the Caribbean,” Lancet, 368(9536), pp. 625–626. doi: 10.1016/S0140-6736(06)69223-4.

Bhatnagar, P. et al. (2016) “Trends in the epidemiology of cardiovascular disease in the UK,” Heart (British Cardiac Society), 102(24), pp. 1945–1952. doi: 10.1136/heartjnl-2016-309573.

Blood Pressure Lowering Treatment Trialists’ Collaboration (2014) “Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data,” Lancet, 384(9943), pp. 591–598. doi: 10.1016/S0140-6736(14)61212-5.

Capodanno, D. and Angiolillo, D. J. (2016) “Aspirin for primary cardiovascular risk prevention and beyond in diabetes mellitus,” Circulation, 134(20), pp. 1579–1594. doi: 10.1161/CIRCULATIONAHA.116.023164.

Cho, M. H. et al. (2018) “Effects of smoking habit change on all-cause mortality and cardiovascular diseases among patients with newly diagnosed diabetes in Korea,” Scientific reports, 8(1). doi: 10.1038/s41598-018-23729-0.

Gasevic, D., Ross, E. S. and Lear, S. A. (2015) “Ethnic differences in cardiovascular disease risk factors: A systematic review of North American evidence,” The Canadian journal of cardiology, 31(9), pp. 1169–1179. doi: 10.1016/j.cjca.2015.06.017.

Ghorpade, A. G. et al. (2015) “Estimation of the cardiovascular risk using World Health Organization/International Society of Hypertension (WHO/ISH) risk prediction charts in a rural population of South India,” International journal of health policy and management, 4(8), pp. 531–536. doi: 10.15171/ijhpm.2015.88.

Grundy, S. M. et al. (2019) “2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: A report of the American college of cardiology/American heart association task force on clinical practice guidelines,” Journal of the American College of Cardiology, 73(24), pp. e285–e350. doi: 10.1016/j.jacc.2018.11.003.

Herttua, K. et al. (2016) “Poor adherence to statin and antihypertensive therapies as risk factors for fatal stroke,” Journal of the American College of Cardiology, 67(13), pp. 1507–1515. doi: 10.1016/j.jacc.2016.01.044.

National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002) “Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report,” Circulation, 106(25), pp. 3143–3421. doi: 10.1161/circ.106.25.3143.

Radovanovic, C. A. T. et al. (2014) “Arterial hypertension and other risk factors associated with cardiovascular diseases among adults,” Revista latino-americana de enfermagem, 22(4), pp. 547–553. doi: 10.1590/0104-1169.3345.2450.

Ramos, R. et al. (2018) “Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study,” BMJ (Clinical research ed.), 362, p. k3359. doi: 10.1136/bmj.k3359.

Rawshani, Aidin et al. (2018) “Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes,” The New England journal of medicine, 379(7), pp. 633–644. doi: 10.1056/NEJMoa1800256.

Stone, N. J. et al. (2014) “2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,” Journal of the American College of Cardiology, 63(25 Pt B), pp. 2889–2934. doi: 10.1016/j.jacc.2013.11.002.

Wong, N. D. et al. (2014) “Preventable coronary heart disease events from control of cardiovascular risk factors in US adults with diabetes (projections from utilizing the UKPDS risk engine),” The American journal of cardiology, 113(8), pp. 1356–1361. doi: 10.1016/j.amjcard.2013.12.042.

World Health Organization (WHO) (2017) On Medicine. Available at: (Accessed: May 22, 2022).